Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Autor: Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC

Publikováno v: International Journal of Nanomedicine, Vol Volume 14, Pp 5751-5752 (2019)

Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article

Externí odkaz: https://doaj.org/article/f7e040c8333d42af9a814346b023d546

Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.

Autor: Wang B; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA., Deng R; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA., Hennig S; Certara, Inc., Princeton, NJ, USA., Badovinac Crnjevic T; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Kaewphluk M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Kågedal M; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA., Quartino AL; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.; Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden., Girish S; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.; Gilead Sciences, Inc., Foster City, CA, USA., Li C; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA., Kirschbrown WP; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. kirschbrown.whitney@gene.com.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Apr; Vol. 89 (4), pp. 571-572.

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.

Autor: Liu SN; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA., Lu T; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA., Jin JY; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA., Li C; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA., Girish S; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA., Melnikov F; Department of Safety Assessment, Genentech, Inc., South San Francisco, California, USA., Badovinac Crnjevic T; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Machackova Z; PDMA-Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Restuccia E; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Kirschbrown WP; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Aug; Vol. 61 (8), pp. 1096-1105. Date of Electronic Publication: 2021 Jul 07.

Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.

Autor: Luo Y; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing., Li W; The First Hospital of Jilin University, Changchun., Jiang Z; Academy of Military Medical Sciences Affiliated Hospital (307 Hospital of PLA), Beijing., Zhang Q; The Tumor Hospital of Harbin Medical University, Harbin., Wang L; Shanghai First People's Hospital, Shanghai.; Current affiliation for Liwei Wang is Renji Hospital, Shanghai., Mao Y; Roche China Holdings, Shanghai.; Current affiliation for Yixiang Mao is Oncology Clinical Research, MSD China, Shanghai, China., Tjan-Heijnen VCG; Maastricht University Medical Center, Maastricht, Netherlands., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., McConnell R; Frontier Science (Scotland) Ltd, Kincraig, Scotland., Bejarano S; Breast International Group, Brussels, Belgium., Fumagalli D; Breast International Group, Brussels, Belgium., Bines J; National Cancer Institute, Rio de Janeiro, Brazil., Wang B; Genentech, Inc., South San Francisco., Garg A; Genentech, Inc., South San Francisco.; Current affiliation for Amit Garg is Seattle Genetics, South San Francisco, California, USA., Kirschbrown WP; Genentech, Inc., South San Francisco., Xu B; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing.

Publikováno v: Anti-cancer drugs [Anticancer Drugs] 2019 Sep; Vol. 30 (8), pp. 866-872.

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Autor: Kirschbrown WP; Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA., Kågedal M; Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA., Wang B; Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA., Lindbom L; qPharmetra, Hälsovägen 7, 141 57, Huddinge, Sweden., Knott A; Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK., Mack R; Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK., Monemi S; Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA., Nijem I; Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA., Girish S; Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA., Freeman C; Breast European Adjuvant Study Team (BrEAST) Data Center, Institut Jules Bordet, Boulevard de Waterloo 121 (7th Floor), 1000, Brussels, Belgium., Fumagalli D; Breast International Group, Boulevard de Waterloo 76, 1000, Brussels, Belgium., McConnell R; Frontier Science (Scotland), Grampian View, Kincraig, Inverness-Shire, PH21 1NA, UK., Jerusalem G; International Breast Cancer Study Group, CHU Liège and Liège University, Domaine Universitaire du Sart Tilman, B35, 4000, Liège, Belgium., Twelves C; University of Leeds and Leeds Teaching Hospitals Trust, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK., Baselga J; Executive Vice-President Research & Development Oncology, AstraZeneca, 950 Wind River Ln, Gaithersburg, MD, 20878, USA., von Minckwitz G; German Breast Group, GBG Forschungs, Martin-Behaim-Str. 12, 63263, Neu-Isenburg, Germany., Bines J; Instituto Nacional de Câncer, Praça Cruz Vermelha, 23-Centro, Rio de Janeiro, 20230-130, Brazil., Garg A; Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA. garg.amit@gene.com.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Jun; Vol. 83 (6), pp. 1147-1158. Date of Electronic Publication: 2019 Apr 11.